免疫治疗与老年黑色素瘤患者总生存期的关联
这项单中心回顾性队列分析纳入92例转移性黑色素瘤患者,接受伊匹木单抗、纳武利尤单抗或帕博利珠单抗治疗。
要点
- 65岁以上转移性黑色素瘤患者免疫治疗后无进展生存期和总生存期更优
- 老年患者与年轻患者的免疫相关不良事件发生率相似
- 年龄可能影响免疫治疗临床结局,需进一步研究验证
核心结论
- 年龄可能与真实世界中免疫治疗后更好的临床结局相关。
研究设计与样本
- 单中心回顾性队列分析,纳入2007年1月至2016年2月在法国里昂南医院接受免疫治疗的92例转移性黑色素瘤患者,共120线治疗。
主要发现
- 常见免疫相关不良事件在两个年龄组中相似。
临床怎么用
- 老年转移性黑色素瘤患者接受免疫治疗时,年龄不应作为排除治疗的依据。
局限性
- 单中心回顾性设计,样本量有限,结果需进一步研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset of patients. Clinical outcomes after treatment by immunotherapy can be influenced by the host's immune system. The immune system is modified with age by age-related immune dysfunction. OBJECTIVE: To evaluate if age influences clinical outcome and immune adverse events in patients treated by immunotherapy for metastatic melanoma. DESIGN, SETTING, AND PARTICIPANTS: This was a single-center cohort analysis in patients treated with immunotherapy for metastatic melanoma between January 2007 and February 2016, in the Lyon Sud Hospital, France. A total of 92 patients with metastatic melanoma treated with ipilimumab, nivolumab, or pembrolizumab were retrospectively analyzed. MAIN OUTCOMES AND MEASURES: Overall survival, progression-free survival, and immune-related adverse events were evaluated for each treatment line according to the patients' age. RESULTS: A total of 92 patients were eligible and included in this study for a total of 120 lines of treatment. Fifty-four patients were included in the cohort that was 65 years or younger (24 [44%] were female; mean [SD] age, 48.1 [12.5] years), and 38 patients were included in the cohort that was older than 65 years (12 [34%] were female; mean [SD] age, 74.8 [6.9] years). Mean follow-up duration starting at treatment initiation was 12.5 months. Patients older than 65 years treated with immunotherapy had a better mean progression-free survival (4.8 vs 3.4 months; P = .04) and overall survival (not reached vs 10.1 months; P = .009) than younger patients in univariate analysis, and after adjusting on prognosis covariates. This was particularly true with patients treated with anti-programmed cell death protein 1. Common immune-related adverse effects were similar in both cohorts. CONCLUSIONS AND RELEVANCE: Age might be associated with a better clinical outcome after treatment with immunotherapy in the real-life setting. In our cohort, older patients did not have more immune-related adverse events. Further studies are warranted to confirm our results and describe the underlying mechanisms involved.
引用
- Perier-Muzet M, Gatt E, Péron J, et al. Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma. JAMA Dermatol. 2018. PMID: 29214290. doi:10.1001/jamadermatol.2017.4584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。